Siemens are no fools.They would not be in our canoe if it didnt...

Siemens are no fools.
They would not be in our canoe if it didnt look as it might float, or have the capacity to represent a potential advance in medical practice.

The above commentary from the EGM highlights an important issue.

"the FDA has been pushing for the industry to get away from gadolinium based contrast agents. These are known to cause some incidents of renal cellular toxicity, even real failure.

And we have a unique platform within MagSense, leveraging our super paramagnetic iron oxide nanoparticles that are safe and are really a fantastic alternative. To gadolinium for clear visualization in MRI scans. Without any exposure to renal toxicity. Importantly, we see this as great step to now redefine the category of molecular imaging, where we can push molecular MRI to the state of the art."

Now think about the journey we have taken, and the next steps. Phase 1 was about patient safety and bio kinetics, with the noted benefit to MRI, that has seen us change commercialization direction, with focus on MRI existing hardware, than the MRX route. As well multiple collaborations.

Its not just about HER2 breast cancer, but a pipeline of others, and all that matters is that the NPs can find their way to the tumor, or clear.
If people were throwing the towel in because of the limited phase 1 trial, where some patients re the cancer had blocked the drainage to lymphs ? consider other types of cancers, where we wont be looking in the lymphatics ? And third party applications. The IP on being able to manufacture these NPs with precision.

Taking a step back, we are at 10m mc, or so. Cheap as chips imo. Thats 0.9c in the old language at 36c today. And that is what the market offers, the emotional who follow the discount conga line, to others who accumulate that opportunity. Its all gambling, and some bets are on the advances the company makes, others are on the reaction that the sheep respond to it. Others are on corporate activity etc. Or other collaborations that are revealed.

Not investment advice.